Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACA | Q13085 | 9/20 | 0.67 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.43 |
| ▸ | FABP1 | P07148 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19834348 | 0.91 | ACACA (0.71) | ACACAACACBGABRA5 | |
| SCHEMBL19834487 | 0.90 | ACACA (0.69) | ACACAACACBGABRA5 | |
| SCHEMBL19834486 | 0.87 | ACACA (0.63) | ACACAACACBGABRA5 | |
| SCHEMBL19834465 | 0.82 | ACACA (0.71) | ACACAFFAR1PPARDACACB | |
| SCHEMBL19834598 | 0.82 | ACACA (0.67) | ACACAFFAR1PPARDACACB | |
| SCHEMBL19834453 | 0.81 | ACACA (1.00) | ACACAACACB | |
| SCHEMBL19834336 | 0.81 | ACACA (1.00) | ACACAACACB | |
| SCHEMBL19834454 | 0.81 | ACACA (0.69) | ACACAACACB | |
| SCHEMBL19834484 | 0.80 | ACACA (0.71) | ACACAFFAR1PPARDACACB | |
| SCHEMBL19834602 | 0.80 | ACACA (0.60) | ACACAFFAR1PPARDACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10252997-B2 | Monocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-04-09 | — | — | US | disclosed |
| US-20180079723-A1 | MONOCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-22 | — | — | US | disclosed |
| EP-3279183-A1 | MONOCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10252997-B2 | Monocyclic compound | FABP1, CPT1A, GOT2 | ACACA 58/4885NR1H4 11/4885DGAT1 176/4885 |
| US-20180079723-A1 | MONOCYCLIC COMPOUND | FABP1, CPT1A, GOT2 | ACACA 58/4885NR1H4 11/4885DGAT1 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.